Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Replimune Group Inc (REPL)
NASDAQ:REPL
Holding REPL?
Track your performance easily
REPL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.92 - $12.97
Previous Close$10.8
Volume600.01K
Average Volume (3M)638.68K
Market Cap
$738.91M
Enterprise Value$345.73M
Total Cash (Recent Filing)$469.12M
Total Debt (Recent Filing)$75.95M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Feb 06, 2025EPS Estimate
-$0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.12
Shares Outstanding68,417,444
10 Day Avg. Volume448,940
30 Day Avg. Volume638,676
Standard Deviation0.23
R-Squared0.07
Alpha0.00204
Financial Highlights & Ratios
Price to Book (P/B)1.97
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.65
Forecast
1Y Price Target
$16.14Price Target Upside49.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Replimune Group News
PremiumCompany Announcements
Replimune Group Advances Cancer Treatment with FDA Submission
PremiumCompany Announcements
Replimune Group’s Q3 2024 Financial Highlights
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
REPL FAQ
What was Replimune Group Inc’s price range in the past 12 months?
Replimune Group Inc lowest stock price was $4.92 and its highest was $12.97 in the past 12 months.
What is Replimune Group Inc’s market cap?
Currently, no data Available
When is Replimune Group Inc’s upcoming earnings report date?
Replimune Group Inc’s upcoming earnings report date is Feb 06, 2025 which is in 75 days.
How were Replimune Group Inc’s earnings last quarter?
Replimune Group Inc released its earnings results on Nov 12, 2024. The company reported -$0.68 earnings per share for the quarter, beating the consensus estimate of -$0.823 by $0.143.
Is Replimune Group Inc overvalued?
According to Wall Street analysts Replimune Group Inc’s price is currently Undervalued.
Does Replimune Group Inc pay dividends?
Replimune Group Inc does not currently pay dividends.
What is Replimune Group Inc’s EPS estimate?
Replimune Group Inc’s EPS estimate is -$0.76.
How many shares outstanding does Replimune Group Inc have?
Replimune Group Inc has 68,417,440 shares outstanding.
What happened to Replimune Group Inc’s price movement after its last earnings report?
Replimune Group Inc reported an EPS of -$0.68 in its last earnings report, beating expectations of -$0.823. Following the earnings report the stock price went down -2.48%.
Which hedge fund is a major shareholder of Replimune Group Inc?
Among the largest hedge funds holding Replimune Group Inc’s share is Baker Bros Advisors LP. It holds Replimune Group Inc’s shares valued at 110M.
---
Replimune Group Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.14 (49.44% Upside)
$16.14 (49.44% Upside)
Blogger Sentiment
Bullish
REPL Sentiment 100%
Sector Average 73%
Sector Average 73%
Insider Transactions
Sold Shares
Worth $91.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.7%
Last 30 Days ▼ 8.5%
Last 30 Days ▼ 8.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.22%
12-Months-Change
Fundamentals
Return on Equity
-50.32%
Trailing 12-Months
Asset Growth
-11.41%
Trailing 12-Months
Company Description
Replimune Group Inc
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in an direct kill turmors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
---
REPL Stock 12 Month Forecast
Average Price Target
$16.14
▲(49.44% Upside)
Technical Analysis
Best Analysts Covering REPL
1 Year
1 Year Success Rate
11/16 ratings generated profit
1 Year Average Return
+17.63%
reiterated a buy rating 10 days ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 68.75% of your transactions generating a profit, with an average return of +17.63% per trade.
---